We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio
Read MoreHide Full Article
AstraZeneca, plc (AZN - Free Report) announced that the FDA has granted approval to a new indication for its breast cancer drug, Faslodex.
The label of Faslodex will now be expanded to include combination use with Eli Lilly’s (LLY - Free Report) new CDK4/6 inhibitor Verzenio/abemaciclib to treat women with HR+, HER2- advanced or metastatic breast cancer whose disease has progressed after endocrine therapy.
The FDA approval was based on the MONARCH 2 study data, which showed that Faslodex+Verzeniosignificantly improved progression-free survival (16.4 months) compared to Faslodex+ placebo.
Shares of this London, United Kingdom based pharma giant have gained 22.2% so far this year, comparing favorably with the industry’s growth of 14%.
In August, Faslodex had received FDA approval for a label extension in the first-line monotherapy setting for the treatment of postmenopausal women with HR+ advanced breast cancer. Until this approval, Faslodex was only approved for advanced breast cancer in later lines of treatment.
We believe that the FDA approval for two new indications for Faslodex in three months can improve sales of the drug in the future quarters. The drug has generated sales of $703 million in 2017 so far, up 16% year over year.
Also, please note that this is the second time that Faslodex has been approved for use in combination with a CDK4/6 inhibitor. It is already marketed in combination with Pfizer’s (PFE - Free Report) Ibrance.
Shares of J&J are up 20.7% so far this year while earnings estimates for 2018 have gone up by 1.2% over the past 30 days.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Image: Bigstock
AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio
AstraZeneca, plc (AZN - Free Report) announced that the FDA has granted approval to a new indication for its breast cancer drug, Faslodex.
The label of Faslodex will now be expanded to include combination use with Eli Lilly’s (LLY - Free Report) new CDK4/6 inhibitor Verzenio/abemaciclib to treat women with HR+, HER2- advanced or metastatic breast cancer whose disease has progressed after endocrine therapy.
The FDA approval was based on the MONARCH 2 study data, which showed that Faslodex+Verzeniosignificantly improved progression-free survival (16.4 months) compared to Faslodex+ placebo.
Shares of this London, United Kingdom based pharma giant have gained 22.2% so far this year, comparing favorably with the industry’s growth of 14%.
In August, Faslodex had received FDA approval for a label extension in the first-line monotherapy setting for the treatment of postmenopausal women with HR+ advanced breast cancer. Until this approval, Faslodex was only approved for advanced breast cancer in later lines of treatment.
We believe that the FDA approval for two new indications for Faslodex in three months can improve sales of the drug in the future quarters. The drug has generated sales of $703 million in 2017 so far, up 16% year over year.
Also, please note that this is the second time that Faslodex has been approved for use in combination with a CDK4/6 inhibitor. It is already marketed in combination with Pfizer’s (PFE - Free Report) Ibrance.
AstraZeneca carries a Zacks Rank #3 (Hold). A better-ranked stock in the large-cap pharma sector is Johnson & Johnson (JNJ - Free Report) with a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Shares of J&J are up 20.7% so far this year while earnings estimates for 2018 have gone up by 1.2% over the past 30 days.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>